51±¾É«

CITCO contributes to national collaboration on advanced single-cell analysis of CAR T cells

Close cooperation between academic and industry partners can advance the development of next-generation cell-based therapies

Newly appointed Associate Professor at CITCO

Collaboration across borders

CITCO engages in collaboration with ATMP-centre in Lund

CITCO 2.0

CITCO extended for an additional five years (2025–2029)

Two New Professors at CITCO

CITCO is strengthened by the appointment of two professors in Hematology Department X. Chief Physician, Ph.D. Thomas Stauffer Larsen, leads the CAR-T cell program in the department and clinical research in the field of lymphoma, while Chief Physician, Ph.D. Henrik Frederiksen becomes head of research and joins CITCO's management team. Both play key roles in CITCO's success in implementing CAR-T cell therapy at OUH. Both professorships are affiliated with the Research Unit for Hematology at the Clinical Institute of the University of Southern Denmark.

JACIE accreditation of CITCO

CITCO has achieved JACIE accreditation, marking an important milestone. This international accreditation is a quality seal for our two departments: Hematology Department X and the Clinical Immunology Department.

First patient with bone marrow cancer treated with CAR-T in Denmark

CITCO has now treated its first myeloma patient with CAR-T cells

Doctor, Ph.D. Mike Bogetofte Barnkob receives an award for his research

Doctor, Ph.D. Mike Bogetofte Barnkob has been honored as the recipient of the 'Exceptional Young Scientist Award' at the Danish Cancer Research Days in Odense, organized by the Danish Comprehensive Cancer Center (DCCC).

Researchers from OUH produce genetically engineered cells on a clinical scale for advanced cancer treatment

First CAR-T product completed at the Department of Clinical Immunology, Odense University Hospital

CAR NK cells - A new weapon against cancer?

CITCO researchers create an overview of clinical experiences with NK cell therapy